【摘要】 目的　观察刺五加对冠心病患者血清超氧化物歧化酶 (SOD)、过氧化脂质 (LPO)、组织型纤维蛋白溶酶原激活物 (t-PA)及组织型纤维蛋白溶酶原激活物抑制剂 (PAO - 1)的影响。方法　将 48例患者分为治疗组和对照组 ,治疗组用刺五加注射液 6 0ml加入 2 5 0ml液体中静滴 ,每天一次 ,共一周 ,余治疗同对照组。结果治疗组血清SOD活力明显增高 (P <0 0 1) ,LPO含量降低 (P <0 0 1) ,对照组SOD活力及LPO含量用药前后无明显改变 (P均 >0 0 5 ) ,血清SOD的含量在治疗组用药前后和对照组皆无明显差别 (均为P >0 0 5 )。治疗组t-PA、PAI- 1明显升高 (P <0 0 1) ,而对照组治疗前后无明显变化 (P >0 0 5 )。结论　刺五加能升高冠心病患者SOD活力、降低LPO含量、提高纤溶功能。更多还原

【Abstract】 Objective To observe the effect of Acanthopanax on superoxide dismutase(SOD),lipid peroxide(LPO),tissue plasminogen activator(t-PA)and plasminogen activator inhibitor(PAI).Methods 48 patients were divided into two groups(acanthopanax treating group and control group).Acanthopanax treating group were given IV 60ml acanthopanax qd for one week and given other treatment the same as control ,s.Results After the treatment with acanthopanax,SOD activity were increased(P<0 01),LOP levels were decreased(P<0 01).SOD and LOP had no any changes in control group(P both >0 05).SOD were found no significant changes in control and acanthopanax treating group(P both>0 05).T-PA and PAI were increased significantly in acanthopanax treating group(P<0 01),but there were ,nt any changes in control group(P>0 05).Conclusion Acanthopanax can increase SOD activity,decrease LOP levels and enhance the activity of fibrinolysis.更多还原